Shire has announced the filing of its first submission to the United States Food and Drug Administration (FDA) for the company’s new plasma manufacturing facility in Covington, Georgia. The facility is expected to add approximately 30% capacity to the company’s internal network once fully operational.
The first submission is for the transfer of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% solution, a replacement therapy for primary humoral immunodeficiency. The company expects to make a second submission to the FDA in 2018 for its albumin therapy, which is primarily used as plasma-volume replacement therapy in immune disorders, trauma and other critical conditions.
The Covington, Georgia site currently employs approximately 900 full-time colleagues and contract employees. The site plans to increase hiring in 2018 to fill roles in manufacturing, quality, engineering, maintenance, utilities, warehouse and a variety of support and facility roles.
Shire also expects to continue expansion of its plasma collection network in Georgia and throughout the United States through its subsidiary, BioLife Plasma Services. BioLife collects the human plasma that will be processed into the drugs manufactured at Shire’s new Covington, Georgia facility.
Shire has experienced significant growth in Immunology, including a +21% increase in September year-to-date product sales in 2017 (on a pro-forma basis).
Matt Walker, Head of Technical Operations for Shire, said: “We are pleased to have filed the Georgia site and look forward to working with the FDA to seek approval for manufacturing in 2018. The additional capacity from this site is a key element to support the growth in our Immunology franchise.”